Brief: PharmaCyte Biotech Begins Studies To Confirm Its Pancreatic Cancer Therapy Can Treat Malignant Ascites
23/05/2022 14:04
May 23 (Reuters) - PharmaCyte Biotech Inc PMCB.O :
* PHARMACYTE BIOTECH INITIATES STUDIES TO CONFIRM ITS
PANCREATIC
CANCER THERAPY CAN TREAT MALIGNANT ASCITES
Source text for Eikon: ID:nBw7GYVzfa
Further company coverage: PMCB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pharmacyte Biotech
See all newsBrief: Pharmacyte Biotech Inc - Increases Stake In Tnf Pharmaceuticals By $3 Million
Brief: PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease
Brief: Pharmacyte Biotech Acquires $5 Million Stake In Emerging Women’S Health Innovator Femasys
Brief: Femasys Inc. Secures Additional Financing With Strategic Investment From Investors Led By Pharmacyte Biotech
Brief: Pharmacyte Biotech Announces Final Results Of Tender Offer